Effective Solutions

Introducing the EVOX performance enhancement system. The EVOX delivers highly-predictable, thorough, and consistent results for a variety of issues dealing with subconscious stress, and PTSD appears to be no exception.

The EVOX measures voice frequencies during a brief recording of the client’s voice. It captures reliable markers of subconscious stress and displays a pattern on your computer screen called a Voice Map. The stress pattern changes depending on the topic spoken of.

Next, the EVOX delivers a signal targeting the stress measured during the recording. During this signal-output phase, clients typically report feeling peaceful and discovering new thoughts and perceptions they had been unable to experience before.

Following signal output, another recording is made. After each of the first few voice maps, the pattern often shows an increase in subconscious stress as it begins to “emerge” and release. After 3-5 voice maps, the pattern typically shows a releasing patterns where the stress vanishes from the quadrant where it had been fixed. At this point, the client can be expected to feel significant relief and to experience increased freedom from previous symptoms.

The exact mechanism that elicits such effects is thus far only theoretical, but the consistently effective results are clearly observable. Anecdotal evidence of its efficacy are abundant.

For example, a doctor brought a vet to my office in 2006 who suffered such extreme anxiety attacks that he had hardly left his house in years. He had constant nightmares as well. After five voice maps, the stress pattern had released and he reported feeling peaceful.

Three weeks later, the doctor dropped by the office and reported that the vet had not suffered a single anxiety attack since his EVOX session, he laughed all the time, and felt better than ever before in his life.

Such results are so typical that when no observable results occur after eight or nine voice maps, I become quite surprised.

EVOX Awareness

I am currently in contact with a high-ranking individual in the military medical establishment to introduce the EVOX as an ideal solution for dealing with PTSD, combat stress, and other performance enhancement. His personal experience and several experiences he has witnessed on other individuals has him convinced and quite excited about the upcoming relief for so many soldiers. We will soon present the system to additional military doctors in order to spread the enthusiasm that is the EVOX’s due.

The EVOX matches perfectly the military’s BICEP program wherein relief from combat stress can be delivered quickly, on location, and return our soldiers to duty in safe mental/emotional condition. The EVOX is completely portable, simple to operate, and extremely cost effective.

PTSD and the “Hot Stove” Effect

PTSD and the “Hot Stove” Effect

The basic cause of PTSD is no mystery. Traumatic experiences trigger what I call the “hot stove effect,” which happens like this: if a child touches a hot stove and burns his hand, the subconscious creates an association between the hot stove and the ensuing pain and injury. The next time it recognizes a hot stove, it spits out neurochemicals called peptides which cause the child to experience fear. This is designed as a protection from further injury.

The problem is that the subconscious often becomes overprotective. For example, if a romantic relationship ends, the pain and heartache may be associated with aspects of the relationship – attraction, vulnerability, etc. When the brain recognizes these elements, it may deliver the same anxiety response as caused by the hot stove.

Thus the subconscious inadvertently inhibits positive aspects of living in its efforts to protect us from pain and damage. Not only relationships may be adversely affected, but work, social situations, crowded, dark, or unfamiliar situations, and even getting out of bed in the morning may become unbearable for the sufferer.

A Sense of Urgency

A Sense of Urgency

Due largely to the large number of soldiers who suffer from combat stress and the difficulty of treating PTSD, Post Traumatic Stress Disorder (or PTSS – Post Traumatic Stress Syndrome) has become one of the most urgent issues facing the military medical establishment.

Known as “shell shock” in earlier wars, PTSD became better known following the Viet Nam war as thousands of vets returned to the USA but never really came home. Uncontrollable and debilitating anxiety obstructed careers, destroyed families, and paralyzed nearly every effort to heal and get on with living.

Initially, an uninformed public callously said “It’s all in your head” and expected vets struggling with PTSD to “deal with it,” but it was not that simple. Thousands of strong, intelligent, brave, competent men became jobless and homeless because they could not just “get over it.”

The current situation is exacerbated by budgets, politics, difficulty in diagnosis, and other factors. For example, because PTSD has often proven “uncurable,” soldiers are reluctant to get checked out since a diagnosis could seriously impede their future military career. The armed forces also increase their financial liability because a PTSD diagnosis may mean a lifetime of counseling expenses.

Faster, Easier, Better Results

Faster, Easier, Better Results

The bioenergetic technology field – with specific applications for medicine, counseling and performance enhancement – is booming. Significant developments over the past decade have raised the bar, and if you’re a medical professional or a patient wanting the best possible care, it’s time you got informed.

Reata gets FDA orphan drug status for bardoxolone methyl to treat PAH

Reata Pharmaceuticals, a US-based developer of breakthrough medicines, has secured orphan drug designation from the FDA Office of Orphan Products Development (OOPD) for bardoxolone methyl to treat pulmonary arterial hypertension (PAH).

Continue reading here:
Reata gets FDA orphan drug status for bardoxolone methyl to treat PAH

New Subtle Energy Pattern Research Shows Increases in Cell Growth and Viability

New Vital Force Technology results show that subtle energy patterns have a significant positive impact on human cell growth. (PRWeb January 13, 2015) Read the full story at http://www.prweb.com/releases/2015/NewSubtleEnergyFindings/prweb12439444.htm

View the original here:
New Subtle Energy Pattern Research Shows Increases in Cell Growth and Viability

Cornerstone Pharmaceuticals' CPI-613 Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting …

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced that its lead compound CPI-613 …

See more here:
Cornerstone Pharmaceuticals' CPI-613 Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting …

Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613 in Relapsed or Refractory AML Patients to be …

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced positive data from an ongoing Phase …

More:
Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613 in Relapsed or Refractory AML Patients to be …

Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Hodgkin's or T-Cell Non …

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical …

More here:
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Hodgkin's or T-Cell Non …

Cornerstone Pharmaceuticals' CPI-613 Phase I Hematologic Malignancies Trial Data Published in AACR's Clinical Cancer …

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that data from the Phase I clinical trial evaluating CPI-613 …

View original post here:
Cornerstone Pharmaceuticals' CPI-613 Phase I Hematologic Malignancies Trial Data Published in AACR's Clinical Cancer …

Researchers create experimental blood test to determine BHI by gauging performance of mitochondria

Researchers at the University of Alabama at Birmingham School of Medicine have created an experimental blood test that, for the first time, determines a “Bioenergetic Health Index,” or BHI, by gauging the performance of mitochondria, the cell's energy powerhouses.

Originally posted here:
Researchers create experimental blood test to determine BHI by gauging performance of mitochondria

New Test Measuring Cell Bioenergetic Health Could Become Key Tool in Personalized Medicine

Researchers at the UAB School of Medicine have created an experimental blood test that, for the first time, determines a Bioenergetic Health Index, by gauging the performance of mitochondria, the cell's energy powerhouses.

See more here:
New Test Measuring Cell Bioenergetic Health Could Become Key Tool in Personalized Medicine